| 2025-12-10 |
详情>>
内部人交易：
Taub Rebecca等共交易21笔
|
| 2025-11-04 |
详情>>
股本变动：
变动后总股本2271.14万股
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-10.32美元,归母净利润-2.3亿美元,同比去年增长43.49%
|
| 2025-11-04 |
财报披露：
美东时间 2025-11-04 盘前发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-5.22美元,归母净利润-1.16亿美元,同比去年增长61.43%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-3.32美元,归母净利润-7323.8万美元,同比去年增长50.36%
|
| 2025-04-29 |
股东大会：
将于2025-06-20召开股东大会
会议内容 ▼▲
- 1.To elect four Class III director nominees named in the accompanying proxy statement to serve on the Board of Directors of the Company, each for a three-year term expiring at the Annual Meeting of Stockholders to be held in 2028 or until their successors are duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement;
4.To vote, on a non-binding, advisory basis, on the frequency of future advisory votes to approve the compensation of our named executive officers;
5.To transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2025-02-26 |
详情>>
业绩披露：
2022年年报每股收益-17.23美元,归母净利润-2.95亿美元,同比去年增长-22.12%
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-21.9美元,归母净利润-4.66亿美元,同比去年增长-24.69%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-19.31美元,归母净利润-4.06亿美元,同比去年增长-55.48%
|
| 2024-08-07 |
详情>>
业绩披露：
2023年中报每股收益-8.91美元,归母净利润-1.63亿美元,同比去年增长-26.86%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益-14.47美元,归母净利润-3亿美元,同比去年增长-84.09%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-7.38美元,归母净利润-1.48亿美元,同比去年增长-91.87%
|
| 2024-04-29 |
股东大会：
将于2024-06-25召开股东大会
会议内容 ▼▲
- 1.To elect three Class II director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2027 or until their successors are duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement;
4.To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035;
5.To transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2024-03-15 |
复牌提示：
2024-03-14 15:29:48 停牌，复牌日期 2024-03-14 16:45:00
|
| 2024-02-28 |
详情>>
业绩披露：
2023年年报每股收益-19.99美元,归母净利润-3.74亿美元,同比去年增长-26.5%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-14.27美元,归母净利润-2.61亿美元,同比去年增长-24.82%
|
| 2023-05-01 |
股东大会：
将于2023-06-15召开股东大会
会议内容 ▼▲
- 1.To elect three Class I director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2026 or until their successors are duly elected and qualified;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.To approve an amendment to the Company’s Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation;
5.To transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2022-05-02 |
股东大会：
将于2022-06-15召开股东大会
会议内容 ▼▲
- 1.to elect three Class III director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2025 or until their successors are duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.to transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.to elect two Class II director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2024 or until their successors are duly elected and qualified;
2.to approve our amended 2015 Stock Plan, which among other things increases the total number of shares of our common stock available for issuance under the 2015 Stock Plan by 1,200,000 shares and incorporates our director equity compensation policy within the Plan terms, in the form attached as Annex A to this proxy statement;
3.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
4.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
5.to transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2020-04-29 |
股东大会：
将于2020-06-17召开股东大会
会议内容 ▼▲
- 1.to elect three Class I director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2023 or until their successors are duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.to transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2019-05-15 |
股东大会：
将于2019-06-27召开股东大会
会议内容 ▼▲
- 1.to elect three Class III director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2022 or until their successors are duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.to approve our amended 2015 Stock Plan, which among other things increases the total number of shares of our common stock available for issuance under the 2015 Stock Plan by 500,000 shares, in the form attached as Annex A to this proxy statement;
4.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
5.to approve, on an advisory basis, the frequency of holding future advisory votes on the compensation of our named executive officers, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
6.to transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-19召开股东大会
会议内容 ▼▲
- 1.to elect two Class II director nominees named in the accompanying proxy statement to serve on the Board of Directors for three-year terms expiring at the Annual Meeting of Stockholders to be held in 2021 or until their successors are duly elected and qualified;
2.to ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
4.to transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-29召开股东大会
会议内容 ▼▲
- 1.To elect two directors to serve three-year terms expiring in 2020;
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.To approve an amendment to our 2015 Stock Plan to increase the total number of shares of our common stock available for issuance under the 2015 Stock Plan by 1,000,000 shares, in the form attached as Annex A to the accompanying proxy statement;
4.To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
5.To transact such other business that is properly presented at the meeting and any adjournments or postponements thereof.
|
| 2016-07-22 |
详情>>
拆分方案：
每35.0000合并分成1.0000股
|
| 2016-06-08 |
股东大会：
将于2016-07-21召开股东大会
会议内容 ▼▲
- 1. To approve the Agreement and Plan of Merger and Reorganization, or the Merger Agreement, dated as of April 13, 2016, by and among Synta Pharmaceuticals Corp., or Synta, Saffron Merger Sub Inc., and Madrigal Pharmaceuticals, Inc., or Madrigal, a copy of which is attached as Annex A to the accompanying proxy statement, and the issuance of shares of Synta common stock to Madrigal stockholders by virtue of the merger contemplated by the Merger Agreement;
2. To approve a certificate of amendment to Synta's restated certificate of incorporation to effect a reverse stock split of Synta's issued and outstanding shares of common stock, in the form attached as Annex C to the accompanying proxy statement, pursuant to which any whole number of outstanding shares between and including twenty (20) and thirty-five (35), such whole number to be determined by the Synta board of directors, would be combined and reclassified into one share of Synta common stock;
3. To approve an amendment to the 2015 Stock Plan to increase the total number of shares of Synta common stock currently available for issuance under the 2015 Stock Plan by 40,000,000 shares, prior to giving effect to the proposed reverse stock split, in the form attached as Annex D to the accompanying proxy statement;
4. To elect one Class III director to Synta's board of directors for a term of three years (provided, however, that if the merger is completed, the board of directors will be reconstituted as provided in the Merger Agreement);
5. To approve, on an advisory basis, the compensation of Synta's named executive officers as disclosed in the accompanying proxy statement, pursuant to the compensation disclosure rules of the Securities and Exchange Commission;
6. To approve, on an advisory basis, the golden parachute compensation that may be paid or become payable to Synta's named executive officers as disclosed in the accompanying proxy statement;
7. To ratify the appointment of Ernst & Young LLP as Synta's independent registered public accounting firm for the fiscal year ending December 31, 2016;
8. To consider and vote on a proposal to adjourn the Annual Meeting, if necessary, to solicit additional proxies, in the event that there are not sufficient votes at the time of the Annual Meeting to approve Proposal Nos. 1, 2 and 3;
9. To consider any other business that is properly brought before the meeting and any adjournments or postponements thereof.
|